Related Experiment Video
Updated: Dec 4, 2025

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
IMMUNODIAGNOSIS IN MEMBRANOUS NEPHROPATHY
Magdalena Ratajczak1, Ewa Poleszak2, Tomasz Chrościcki3
1EUROIMMUN POLAND A PERKINELMER COMPANY, WROCLAW, POLAND.
Abstract:
One of the diseases leading to chronic end-stage renal disease is membranous nephropathy (MN). The main cause of this disease is the formation of antibodies to foreign and native antigens. Membranous nephropathy can be conventionally divided into 2 types: primary form (when the primary disease is unknown) and secondary form. Detection of appropriate antibodies is one of the methods to recognize and differentiate primary and secondary forms. A large role in non-invasive diagnosis of MN and differentiation of the primary form from the secondary play antinuclear antibodies (ANA), antibodies against granulocyte cytoplasm (ANCA), antiglomerular basement antibodies (anti-GBM) and phospholipase A2 receptor antibodies (anti-PLA2R). Differentiation matters when choosing a treatment choice. In the primary form, it is immunosuppression, and in the form of secondary treatment, it consists in curing or controlling diseases that can cause symptoms of MN. The aim: Analysis of serological methods helpful in immunodiagnosis of membranous nephropathy.
Insights
Diagnosing membranous nephropathy (MN) involves identifying specific antibodies. Differentiating primary MN from secondary MN using serological tests like anti-PLA2R antibodies is crucial for effective treatment strategies.
Area of Science:
- Nephrology
- Immunology
- Clinical Diagnostics
Background:
- Membranous nephropathy (MN) is a leading cause of chronic kidney disease.
- Antibody formation against glomerular antigens triggers MN.
- MN is classified as primary (idiopathic) or secondary (associated with other conditions).
Purpose of the Study:
- To analyze serological methods for the immunodiagnosis of membranous nephropathy.
- To highlight the role of specific antibodies in differentiating primary and secondary MN.
- To emphasize the clinical significance of accurate MN subtyping for treatment selection.
Main Methods:
- Review of serological markers including antinuclear antibodies (ANA), antibodies against granulocyte cytoplasm (ANCA), anti-glomerular basement antibodies (anti-GBM), and phospholipase A2 receptor antibodies (anti-PLA2R).
- Analysis of the diagnostic utility of these antibodies in distinguishing MN subtypes.
- Evaluation of non-invasive diagnostic approaches for MN.
Main Results:
- Specific antibodies like anti-PLA2R are key in diagnosing and differentiating primary MN.
- ANA, ANCA, and anti-GBM antibodies also play roles in MN subtyping.
- Accurate serological differentiation guides appropriate therapeutic interventions.
Conclusions:
- Serological testing is essential for the accurate immunodiagnosis of membranous nephropathy.
- Distinguishing between primary and secondary MN through antibody detection is critical for personalized treatment.
- Targeted immunosuppression for primary MN versus addressing underlying causes for secondary MN improves patient outcomes.
More Related Videos
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction

